Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
Loading...
Identifiers
Publication date
Authors
Ebert, Thomas
Anker, Stefan D.
Ruilope Urioste, Luis Miguel
Fioretto, Paola
Fonseca, Vivian
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
To explore whether insulin resistance, assessed by estimated glucose disposal rate (eGDR), is associated with cardiorenal risk and whether it modifies finerenone efficacy. Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Ebert, T., Anker, S. D., Ruilope, L. M., Fioretto, P., Fonseca, V., Umpierrez, G. E., Birkenfeld, A. L., Lawatscheck, R., Scott, C., Rohwedder, K., Rossing, P., & FIDELIO-DKD and FIGARO-DKD Investigators. (2024). Outcomes with finerenone in patients with chronic kidney disease and type 2 diabetes by baseline insulin resistance. Diabetes Care, 47(3), 362-370. https://doi.org/10.2337/dc23-1420